Eli Lilly and Company (ETR:LLY)

Market Cap	643.72B
Revenue (ttm)	45.35B
Net Income (ttm)	11.75B
Shares Out	n/a
EPS (ttm)	13.02
PE Ratio	54.78
Forward PE	29.65
Dividend	5.29 (0.73%)
Ex-Dividend Date	Aug 15, 2025

Volume	2,721
Average Volume	3,971
Open	737.40
Previous Close	736.40
Day's Range	728.20 - 749.00
52-Week Range	535.80 - 888.30
Beta	0.46
RSI	70.61
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD